Medical Condition News

RSS

CompCare signs contract to provide autism care coordination services in Wisconsin

Comprehensive Care Corporation today announced it has signed a contract effective March 1, 2010, to provide autism care coordination services for a health plan in Wisconsin.

30 Mar 2010

New therapeutic approaches against lymphoid tumors

Helmholtz Zentrum M-nchen has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

30 Mar 2010

Study: Hormone replacement in joint fluid might be beneficial in treating osteoarthritis

German researchers determined that concentrations of the sex hormones, testosterone in men and estrogen in women, may have a positive effect on the regenerative potential of cartilage tissue. The study suggests hormone replacement in the joint fluid of men and women might be beneficial in treating late stages of human osteoarthritis by regenerating damaged tissue.

30 Mar 2010

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation.

30 Mar 2010

Decision Resources: Only 52.2% of first-line Alzheimer's disease patients prescribed AChEI

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while approximately 70 percent of surveyed physicians' newly diagnosed patients have mild-to-moderate Alzheimer's disease, only 52.2 percent of first-line patients are prescribed an acetylcholinesterase inhibitor.

30 Mar 2010

Rite Aid, AAAAI team up to offer guides to allergy sufferers

Rite Aid and the American Academy of Allergy, Asthma & Immunology are again teaming up this spring to help allergy sufferers with free allergy guides available now in nearly 4,800 Rite Aid stores nationwide and online at www.riteaid.com.

30 Mar 2010

Acupuncture can help calm anxiety related to dental treatment

Acupuncture can calm highly anxious dental patients and ensure that they can be given the treatment they need, suggests a small study published in Acupuncture in Medicine.

30 Mar 2010

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.

30 Mar 2010

LeAnn Rimes encourages psoriasis patients to take Make a Change Pledge

Grammy Award-winning multi-platinum recording artist and psoriasis patient LeAnn Rimes is calling for people with psoriasis to pledge to better manage their disease as part of the awareness campaign "Stop Hiding from Psoriasis." In partnership with the American Academy of Dermatology and National Psoriasis Foundation, LeAnn is encouraging people to take a stand against psoriasis by taking the Make a Change Pledge online at StopHiding.org.

30 Mar 2010

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Enobia Pharma Inc. unveiled findings from the first hypophosphatasia self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical Genetics Meeting.

30 Mar 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.

30 Mar 2010

GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer

GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.

30 Mar 2010

Researchers to study health literacy among Indigenous people living with cardiovascular disease

Researchers at St. Michael's Hospital in Toronto are part of an international team of researchers recently awarded a multi-million dollar grant for their work in cardiovascular disease among Indigenous people in Canada, Australia and New Zealand. The Canadian team will receive $742,000 in funding for its part of the project from the Canadian Institutes of Health Research and International Collaborative Indigenous Health Research Partnerships.

30 Mar 2010

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Cephalon, Inc. today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

30 Mar 2010

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.

29 Mar 2010

Unrestricted availability of food can trigger overconsumption and obesity

Some of the same brain mechanisms that fuel drug addiction in humans accompany the emergence of compulsive eating behaviors and the development of obesity in animals, according to research funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.

29 Mar 2010

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

Oxygen Biotherapeutics commences distributing newly formulated Dermacyte Oxygen Concentrate

Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.

29 Mar 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

Medical Condition News

CompCare signs contract to provide autism care coordination services in Wisconsin

New therapeutic approaches against lymphoid tumors

Study: Hormone replacement in joint fluid might be beneficial in treating osteoarthritis

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

Decision Resources: Only 52.2% of first-line Alzheimer's disease patients prescribed AChEI

Rite Aid, AAAAI team up to offer guides to allergy sufferers

Acupuncture can help calm anxiety related to dental treatment

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

LeAnn Rimes encourages psoriasis patients to take Make a Change Pledge

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer

Researchers to study health literacy among Indigenous people living with cardiovascular disease

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

Unrestricted availability of food can trigger overconsumption and obesity

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Oxygen Biotherapeutics commences distributing newly formulated Dermacyte Oxygen Concentrate

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News